Antimicrobial susceptibility profile of ceftolozane/tazobactam, ceftazidime/avibactam and cefiderocol against carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Türkiye.

Ecem BuyukyanboluLeyla GencElizabeth A CyrMehmet KarakusFusun ComertBaris OtluElif AktasDavid P Nicolau

Published in: European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology (2024)

While ceftolozane/tazobactam and ceftazidime/avibactam remained highly active against CR-PA devoid of carbapenemases, cefiderocol provided potent in vitro activity irrespective of carbapenemase production. When considering the potential clinical utility of newer agents against CR-PA, regional variations in carbapenemase prevalence must be considered.

Keyphrases

gram negative
multidrug resistant
klebsiella pneumoniae

pseudomonas aeruginosa
acinetobacter baumannii
drug resistant

cystic fibrosis
risk factors
biofilm formation

anti inflammatory
escherichia coli
climate change